Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.47 | N/A | +19.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.47 | N/A | +19.14% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding current market conditions. They indicated that the company is focusing on long-term strategies despite short-term challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
The earnings report shows that Kodiak Sciences Inc had a larger-than-expected loss per share, which was a positive surprise compared to analyst expectations. However, the lack of revenue data and no guidance may have contributed to the stock's decline of 1.75%. Investors are likely concerned about the company's future performance amidst ongoing market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TAKE-TWO INTERACTIVE
Nov 7, 2022